TET1 and metabolic dysfunction-associated steatotic liver disease: To investigate if targeting TET1 with a small molecule inhibitor can alleviate MASLD progression, we challenged MASLD mice with a TET1 inhibitor (TET1 i) (Jiang et al, 2017), UC514321, for 8 weeks (Fig. 7A).